Study comparing CSA to CSA + ATG from 1999 It showed that the combination of Anti-thymocyte globulin and cyclosporine was superior in terms of response rates. There was no difference in survival at 6 months (93% and 91%, so both groups did very well).
Large EMBT Study showing the outcome in three age groups after treatment with CSA or ATG. Age groups were under 50, 50-60 and 60+. 5-year Survival was 67%, 57% and 50%, respectively. Survival was also influenced by neutrophil count at diagnosis (<200,>500).
Interesting study showing that HD cyclophosphamide (200mg/kg giver IV over 4 days) induce good, durable responses. Age group was 40 to 70. The patients were previously untreated.
tirsdag den 8. juni 2010
fredag den 5. marts 2010
tirsdag den 19. januar 2010
torsdag den 14. januar 2010
Benign Hematology
ITP
Is there a difference between treating with prednisone and dexamethasone? This Italian study examines the question by comparing two prospective series of patients treated with HD-DEX with historical controls. The response rate in the two studies were very good. This figure (1A) shows the fate of the 33 responders out of the 37 in the study. 58% of the responders maintained their reponse at 50 months.
EDTA-dependent pseudo-thrombocytopenia
Large Spanish population study, showing that 0.15% of 20000 individuals have pseudo-thrombocytopenia.
Then this Italian study showed that, at their center, 15% of patients referred for asymptomatic thrombocytopenia has pseudo.
The causative antibodies can be of IgG, IgM or, most commonly, IgG. Some 20% have no detectable antibodies. There is no correlation with lymphoproliferative disease. Study here.
Soluble transferrin receptor. This test is rarely used. The reference interval is a little shifty, but this Finnish study in Blood from 1998 pinned it 1.3-3.3.
Staging
Prognosis
Treatment
Links
Is there a difference between treating with prednisone and dexamethasone? This Italian study examines the question by comparing two prospective series of patients treated with HD-DEX with historical controls. The response rate in the two studies were very good. This figure (1A) shows the fate of the 33 responders out of the 37 in the study. 58% of the responders maintained their reponse at 50 months.
EDTA-dependent pseudo-thrombocytopenia
Large Spanish population study, showing that 0.15% of 20000 individuals have pseudo-thrombocytopenia.
Then this Italian study showed that, at their center, 15% of patients referred for asymptomatic thrombocytopenia has pseudo.
The causative antibodies can be of IgG, IgM or, most commonly, IgG. Some 20% have no detectable antibodies. There is no correlation with lymphoproliferative disease. Study here.
Soluble transferrin receptor. This test is rarely used. The reference interval is a little shifty, but this Finnish study in Blood from 1998 pinned it 1.3-3.3.
Staging
Prognosis
Treatment
Links
Abonner på:
Opslag (Atom)